Actively Recruiting

Age: 18Years +
All Genders
NCT06367582

Spine Bone Cements Outcomes - Post Market Follow-up

Led by Teknimed · Updated on 2025-09-09

500

Participants Needed

12

Research Sites

1047 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

A Post-Market Clinical Follow-Up (PMCF) Study to collect clinical data on safety and performance of all TEKNIMED Spine range of products: SPINEFIX, HIGH V+, OPACITY+ and F20 bone cements and mixing and injection systems, and all their private labels. TEKNIMED bone cements are legacy products, some marketed for more than 10 years. Their performance and safety have already been demonstrated by Post-Market Surveillance and previous clinical studies. The current Post-Market Clinical Follow-Up study aims to confirm these claims by collecting data in a "real-life" setting. The study is a retrospective and prospective global, single arm, non-controlled, multicentric, prospective observational study. Patients will be followed as per local standard medical care of the sites.

CONDITIONS

Official Title

Spine Bone Cements Outcomes - Post Market Follow-up

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Be 18 years or older
  • Be willing to sign an informed consent approved by Ethic Committee (when applicable) or not be opposed to use of clinical data
  • For prospective inclusion: considered for treatment with one of the TEKNIMED Spine Range cements in this study
  • For retrospective inclusion: have undergone surgery with a TEKNIMED Spine Range cement since January 1, 2016, and not oppose use of clinical data or be willing to sign informed consent at first follow-up (when applicable)
Not Eligible

You will not qualify if you...

  • Procedures other than those stated in the indications
  • Coagulation disorders or severe cardiopulmonary disease
  • Unstable vertebral fractures
  • Compromise of the vertebral body or pedicle walls
  • Hypersensitivity or allergy to any constituents of the product
  • Patient clearly improving with more conservative treatment
  • Prophylactic use in spinal metastatic or osteoporotic patients without evidence of acute fracture
  • Pediatric patients
  • Pregnant or breastfeeding women

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 12 locations

1

CHU HautePierre

Strasbourg, Bas-Rhin, France, 67200

Actively Recruiting

2

Pôle Rachis Hôpital Privé d'Eure et Loir

Mainvilliers, Eure et Loir, France, 28300

Actively Recruiting

3

Hôpital Toulouse Purpan

Toulouse, Haute Garonne, France, 31130

Actively Recruiting

4

Pôle Sud Santé

Le Mans, Sarthe, France, 72100

Actively Recruiting

5

Centre Hospitalier Métropole Savoie

Chambéry, Savoie, France, 73000

Actively Recruiting

6

Hospitale Cruz Vermelha Portuguesa

Lisbon, Portugal, 1549-008

Actively Recruiting

7

Clínica Teknon Instituto de neurociencias

Barcelona, Spain, 08022

Actively Recruiting

8

Hospital Neurotraumatologico

Granada, Spain, 18013

Actively Recruiting

9

Hospital Clínico Universitario Virgen de la Arrixaca

Murcia, Spain, 30120

Actively Recruiting

10

Fundacio Assistencial Mutua de Terrassa - Edifici Estació

Terrassa, Spain, 08222

Actively Recruiting

11

Hospital de Zafra

Zafra, Spain, 06300

Actively Recruiting

12

Institute of Traumatology and Orthopaedics

Kiev, Ukraine, 1601

Actively Recruiting

Loading map...

Research Team

S

Solange VAN DE MOORTELE, PhD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

9

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Spine Bone Cements Outcomes - Post Market Follow-up | DecenTrialz